Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075104 Target Snapshot

Leucine-rich repeat serine/threonine-protein kinase 2 · SINGLE PROTEIN · Homo sapiens

5,364Compounds
761Assays
16Approved Drugs
8,141.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q5S007. Use UniProt Q5S007 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q5S007 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leucine-rich repeat serine/threonine-protein kinase 2 as ChEMBL target CHEMBL1075104, mapped to UniProt Q5S007. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leucine-rich repeat serine/threonine-protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1075104
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q5S007
Leucine-rich repeat serine/threonine-protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Leucine-rich repeat serine/threonine-protein kinase 2 is the right protein anchor across sources, using UniProt Q5S007 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLeucine-rich repeat serine/threonine-protein kinase 2
UniProt AccessionQ5S007
Component TypeProtein
Sequence Length2527 aa

Leucine-rich repeat serine/threonine-protein kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Leucine-rich repeat serine/threonine-protein kinase 2, mapped to UniProt Q5S007. Sequence length is 2527 aa.

Mapped IDQ5S007
Review nameLeucine-rich repeat serine/threonine-protein kinase 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

16
Approved
13
Phase III
10
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC506,621.0
KI1,138.0
EC50230.0
KD152.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3969077 10.22 Ki 0.06 Preclinical
CHEMBL5189225 10.19 IC50 0.06457 Preclinical
CHEMBL5195441 10.12 IC50 0.07586 Preclinical
CHEMBL5283143 10.09 IC50 0.08128 Preclinical
CHEMBL5273196 10.09 IC50 0.08128 Preclinical
CHEMBL5266868 10.09 IC50 0.08128 Preclinical
CHEMBL5198416 10.09 IC50 0.08128 Preclinical
CHEMBL5177202 10.09 IC50 0.08128 Preclinical
CHEMBL5191262 10.09 IC50 0.08128 Preclinical
CHEMBL5171075 10.09 IC50 0.08128 Preclinical
Distribution

pChEMBL Value Distribution

196
5.0
263
5.5
761
6.0
712
6.5
964
7.0
842
7.5
887
8.0
540
8.5
238
9.0
21
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
PONATINIB
CHEMBL1171837
Approved 2012
AXITINIB
CHEMBL1289926
Approved 2012
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

761
Total Assays
3,591
Tested Compounds
3
Assay Types
Binding — 751 assays, 3,591 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 436 2,848 7.5
cell-based format 184 498 7.0
assay format 123 243 7.0
subcellular format 8 2 8.0
ADME — 7 assays, 18 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 6 6 7.0
single protein format 1 12 7.6
Functional — 3 assays, 199 compounds
BAO Format Assays Compounds Avg pChEMBL
subcellular format 2 1 7.3
assay format 1 198 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine